Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$44.12 -3.5%	$37.08	$19.45 ▼ $53.27	$2.87B	2.07	626,239 shs	3.80 million shs
MLTX MoonLake Immunotherapeutics	$47.52 +0.5%	$41.82	$31.42 ▼ $58.26	$3.04B	1.23	384,473 shs	923,933 shs
MTSR Metsera	$28.59 -0.4%	$26.70	$12.30 ▼ $37.99	$3.00B	N/A	1.02 million shs	932,237 shs
QURE uniQure	$13.86 -2.6%	$14.52	$3.73 ▼ $19.18	$759.20M	0.08	1.97 million shs	836,500 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	0.00%	-3.82%	+45.85%	+48.95%	+47.61%
MLTX MoonLake Immunotherapeutics	0.00%	+9.24%	+21.97%	+19.22%	+18.24%
MTSR Metsera	0.00%	-3.41%	+3.62%	+2.11%	+2,858,999,900.00%
QURE uniQure	0.00%	-2.46%	-6.98%	+11.15%	+215.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KYMR Kymera Therapeutics	2.8072 of 5 stars	4.5	1.0	0.0	0.0	3.0	1.7	0.0
MLTX MoonLake Immunotherapeutics	2.258 of 5 stars	3.5	1.0	0.0	0.0	3.3	2.5	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QURE uniQure	2.0252 of 5 stars	3.5	1.0	0.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYMR Kymera Therapeutics	3.00	Buy	$59.61	35.11% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$74.50	56.78% Upside
MTSR Metsera	3.00	Buy	$55.00	92.37% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	172.86% Upside

Current Analyst Ratings Breakdown

Latest QURE, MTSR, KYMR, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00
6/3/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $60.00
6/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$49.00 ➝ $79.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYMR Kymera Therapeutics	$47.07M	61.04	N/A	N/A	$12.90 per share	3.42
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A
QURE uniQure	$27.12M	28.00	N/A	N/A	($0.14) per share	-99.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)

Latest QURE, MTSR, KYMR, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYMR Kymera Therapeutics	N/A	8.49	8.49
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
MTSR Metsera	N/A	6.55	6.55
QURE uniQure	1.53	11.99	11.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYMR Kymera Therapeutics	N/A
MLTX MoonLake Immunotherapeutics	93.85%
MTSR Metsera	N/A
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
KYMR Kymera Therapeutics	16.01%
MLTX MoonLake Immunotherapeutics	12.02%
MTSR Metsera	N/A
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.32 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A
QURE uniQure	500	54.78 million	52.15 million	Optionable

QURE, MTSR, KYMR, and MLTX Headlines

Recent News About These Companies

uniQure (NASDAQ:QURE) Share Price Passes Below Fifty Day Moving Average on Insider Selling

June 25, 2025 | americanbankingnews.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

April 21, 2025 | zacks.com

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold

April 21, 2025 | seekingalpha.com

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

April 21, 2025 | seekingalpha.com

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

April 17, 2025 | globenewswire.com

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

February 27, 2025 | zacks.com

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

February 27, 2025 | globenewswire.com

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

February 7, 2025 | benzinga.com

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

February 7, 2025 | prnewswire.com

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

February 3, 2025 | globenewswire.com

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

January 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks

QURE, MTSR, KYMR, and MLTX Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

$44.12 -1.59 (-3.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$44.12 0.00 (0.00%)

As of 06/27/2025 07:24 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$47.52 +0.23 (+0.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$45.88 -1.65 (-3.46%)

As of 06/27/2025 04:44 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Metsera NASDAQ:MTSR

$28.59 -0.12 (-0.42%)

As of 06/27/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

uniQure NASDAQ:QURE

$13.86 -0.37 (-2.60%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.87 +0.01 (+0.07%)

As of 06/27/2025 07:57 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time